Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in HCC with Microvascular Invasion After Radical Resection
NCT02867280Phase 3Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Started Jun 2016; status: terminated.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02867280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867280.